JP2024527034A - 若年性左心低形成症候群の治療における間葉系幹細胞の使用 - Google Patents

若年性左心低形成症候群の治療における間葉系幹細胞の使用 Download PDF

Info

Publication number
JP2024527034A
JP2024527034A JP2024504874A JP2024504874A JP2024527034A JP 2024527034 A JP2024527034 A JP 2024527034A JP 2024504874 A JP2024504874 A JP 2024504874A JP 2024504874 A JP2024504874 A JP 2024504874A JP 2024527034 A JP2024527034 A JP 2024527034A
Authority
JP
Japan
Prior art keywords
patient
administration
change
stem cells
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527034A5 (cg-RX-API-DMAC7.html
Inventor
ジョシュア エム. ハレ,
サンジェイ カウシャル,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of JP2024527034A publication Critical patent/JP2024527034A/ja
Publication of JP2024527034A5 publication Critical patent/JP2024527034A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024504874A 2021-07-26 2022-07-26 若年性左心低形成症候群の治療における間葉系幹細胞の使用 Pending JP2024527034A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203519P 2021-07-26 2021-07-26
US63/203,519 2021-07-26
PCT/US2022/038370 WO2023009537A1 (en) 2021-07-26 2022-07-26 Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome

Publications (2)

Publication Number Publication Date
JP2024527034A true JP2024527034A (ja) 2024-07-19
JP2024527034A5 JP2024527034A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=83049982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504874A Pending JP2024527034A (ja) 2021-07-26 2022-07-26 若年性左心低形成症候群の治療における間葉系幹細胞の使用

Country Status (9)

Country Link
US (1) US20240350549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376950A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527034A (cg-RX-API-DMAC7.html)
KR (1) KR20240040776A (cg-RX-API-DMAC7.html)
CN (1) CN117999082A (cg-RX-API-DMAC7.html)
AU (1) AU2022316959A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227475A1 (cg-RX-API-DMAC7.html)
TW (1) TW202321437A (cg-RX-API-DMAC7.html)
WO (1) WO2023009537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025062365A1 (en) * 2023-09-22 2025-03-27 Mesoblast International Sárl Mesenchymal lineage precursor or stem cells (mlpscs) for use in methods of treating congenital heart disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806587RA (en) 2016-02-04 2018-09-27 Longeveron Llc Mesenchymal stem cells as vaccine adjuvants and methods for using the same
TW201831681A (zh) 2016-11-11 2018-09-01 美商生命科學公司 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
US12496316B2 (en) 2017-06-19 2025-12-16 Longeveron Inc. Treatment of sexual dysfunction and improvement in sexual quality of life
MX2022003593A (es) * 2019-09-24 2022-09-19 Mezzion Pharma Co Ltd Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM HEART J, vol. 192, JPN6026020255, October 2017 (2017-10-01), pages 48 - 56, ISSN: 0005869398 *
J EXTRACELL VESICLES, vol. vol. 9(S1), article no. 1784511, JPN6026020254, 2020, pages 63, ISSN: 0005869397 *

Also Published As

Publication number Publication date
CA3227475A1 (en) 2023-02-02
KR20240040776A (ko) 2024-03-28
US20240350549A1 (en) 2024-10-24
EP4376950A1 (en) 2024-06-05
TW202321437A (zh) 2023-06-01
CN117999082A (zh) 2024-05-07
AU2022316959A1 (en) 2024-02-29
WO2023009537A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
Agarwal et al. Residual lesions in postoperative pediatric cardiac surgery patients receiving extracorporeal membrane oxygenation support
Rupp et al. Intracoronary bone marrow cell application for terminal heart failure in children
Zhao et al. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery
Tarui et al. Stem cell therapies in patients with single ventricle physiology
Povsic et al. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations
Wacławski et al. Aortic balloon valvuloplasty as a bridge-to-decision in patients with aortic stenosis
Abid et al. Unrepaired persistent truncus arteriosus in a 38-year-old woman with an uneventful pregnancy
US20240350549A1 (en) Use of Mesenchymal Stem Cells in Treatment of Juvenile Hypoplastic Left Heart Syndrome
Haller et al. Surgical strategies in single ventricle management of neonates and infants
HK40103434A (zh) 间充质干细胞在治疗青少年左心发育不良综合征中的用途
Oka et al. Percutaneous atrial septal defect closure in adult Ebstein's anomaly with exertional hypoxemia
Wehman et al. Stem cell therapy for CHD: towards translation
Holst et al. From safety to benefit in cell delivery during surgical repair of Ebstein anomaly: initial results
Fujito et al. Fatal embolic ST-elevation myocardial infarction secondary to healed-phase mitral valve infective endocarditis
Aoyagi et al. Ebstein’s anomaly in adult patients over 50 years of age
Magkiosis et al. A patient with previously corrected partial atrioventricular septal defect, lost to follow-up and re-diagnosed on cardiac MRI.
Lacy-Niebla et al. Surgical treatment of intracardiac teratoma in a 66 years-old man. Case report
Tabbah et al. Surviving a single ventricle and a single atrium with a situs inversus viscerum
Qiu et al. Congenital atresia of the left main coronary artery with left ventricular noncompaction: From infancy to adulthood
Shah et al. Early outcomes of total correction in tetralogy of Fallot in a tertiary care hospital of Peshawar, Khyber Pakhtunkhwa, Pakistan; a two-year retrospective study
Selvan et al. Long-term follow-up of persistent truncus arteriosus: Kuwait experience
Ristić-AnĎelkov et al. PRESENTING WITH A LEFT VENTRICULAR FAIILURE NEKOMPAKTNA LEVA KOMORA KAO UZROK SRČANE SLABOSTI
Gery et al. Comparing outcomes of active closure versus natural evolution in hemodynamically significant restrictive PmVSDs: Insights from the FRANCISCO cohort
Sughimoto et al. Fontan completions over 10 years after Glenn procedures
Soebroto et al. Successful total correction of Transposition of Great Artery in Surabaya’s rural area experience: serial cases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250728

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526